© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Tara K. Iyer, MD
Articles
Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms
November 19, 2025
Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.
Managing Vasomotor Symptoms With NK3 Receptor Antagonism
November 19, 2025
Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.
NK Receptor Antagonism as Therapeutic Strategy for Vasomotor Symptoms
November 12, 2025
Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.
Unmet Needs in Managing Vasomotor Symptoms in Menopause
November 12, 2025
Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.
Impact of Vasomotor Symptoms on Patient Quality of Life
November 05, 2025
Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.
Pathophysiology of Vasomotor Symptoms in Menopause
November 05, 2025
Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.
Educating Patients and Providers: Key Takeaways for Better VMS Management
March 28, 2025
Panelists discuss how providers should actively screen for vasomotor symptoms (VMS), especially given the lengthy wait times to see specialists, emphasizing that education for both patients and health care providers is essential for timely intervention and effective management.
Understanding the Link Between Elinzanetant and Somnolence
March 28, 2025
Panelists discuss how there is no change in therapeutic indication based on this particular finding, though it may serve as a beneficial side effect for patients struggling with sleep difficulties.
Long-Term Safety of New VMS Agents: What We Know So Far
March 28, 2025
Panelists discuss how long-term safety data for fezolinetant and elinzanetant remain unavailable, though short-term results show very positive outcomes with significantly higher efficacy than previous treatment options.
Liver Safety and Monitoring in VMS Treatment
March 28, 2025
Panelists discuss how fezolinetant and elinzanetant can cause liver-related adverse events requiring careful monitoring for drug-induced liver injury, noting that patients typically recover after discontinuation and emphasizing that primary providers are ideally positioned to manage patients with complex comorbidities.